Search results
Showing 181 to 195 of 489 results for %s
This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.
This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.
AnaConDa-S for sedation with volatile anaesthetics in intensive care (MIB229)
This advice has been updated and replaced by NICE healthtech guidance 607.
NICE has developed a medtech innovation briefing (MIB) on Optilume for anterior urethral strictures .
Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)
Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making
myAIRVO2 for the treatment of chronic obstructive pulmonary disease (MIB161)
NICE has developed a medtech innovation briefing (MIB) on myAIRVO2 for the treatment of chronic obstructive pulmonary disease .
indication that the device is feasible for routine use. The identified device(s) should then be formally evaluated in a large-scale...
NICE has developed a medtech innovation briefing (MIB) on the ATEC breast biopsy system
Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (MTG65)
We have moved Medical technologies guidance 65 to become HealthTech guidance 607. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Interim methods guide for developing service guidance 2014 (PMG8)
This manual provides information additional to that in Developing NICE guidelines: the manual to guide developers on how to approach developing service guidance, and also to inform stakeholders about the steps that NICE will take in developing this guidance
ethical requirements of an RCT, as no consensus currently exists about the point(s) at which it may be safe to stop treatment. Source...
wards where training is delivered by a professional trainer and service user(s). Satisfaction with care and other aspects of service...
NICE technology appraisal and highly specialised technologies guidance: the manual (PMG36)
This guide describes the methods and processes, including expected timescales, that NICE follows when carrying out health technology evaluations. The methods and processes are designed to produce robust guidance for the NHS in an open, transparent and timely way, with appropriate contribution from stakeholders. Organisations invited to contribute to health technology evaluation development should read this manual in conjunction with the NICE health technology evaluation topic selection: the manual. All documents are available on the NICE website
NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .
QuikRead go for C-reactive protein testing in primary care (MIB78)
NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care